Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02641028 | A Study in a Human Laboratory Model of Smoking Behavior | PHASE2 | COMPLETED | 71 | — | — | Dec 31, 2015 | Dec 31, 2016 | Apr 27, 2025 | 3 | United States |
Latency (in minutes and seconds) to time of first cigarette smoked during the delay period
Number of cigarettes smoked during the self administration period
| Arm | Type | Description |
|---|---|---|
| CERC-501 | EXPERIMENTAL | Administered orally once daily, 15mg daily, 8 days. |
| Placebo | PLACEBO_COMPARATOR | Administered orally daily, 8 days. |
| Name | Type | Description |
|---|---|---|
| CERC-501 | DRUG | CERC-501 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Provides written informed consent and agrees to complete required clinic visits 2. Male or female 21 to 60 years of age inclusive 3. Body mass index (BMI) 18.5 to 40 kg/m2 inclusive 4. Heavy Smokers 5. Currently not seeking smoking cessation therapy 6. In otherwise good gener...